IBC's Adaptive Designs Conference Builds Upon the Success of Its Inaugural Event
Posted on: Friday, 14 October 2005, 12:00 CDT
WESTBOROUGH, Mass., Oct. 14 /PRNewswire/ -- IBC Life Sciences Second Annual Implementing Adaptive Designs for Drug Development will be held on November 7-8, 2005 at the Nassau Inn in Princeton, New Jersey (http://www.ibclifesciences.com/3136). The conference takes a close look at the advantage and challenges of implementing adaptive designs with a goal to encourage wider deployment of innovative drug development strategies. Adaptive Designs offer an opportunity to improve the quality and efficiency of decision-making in drug development. So why are they not yet more widely used?
A feature presentation, Astrid Heinicke Ph.D., Federal Institute for Drugs and Medical Devices will speak on "A Regulatory View on Adaptive Designs in a Confirmatory Trial." Incorporating interim analyses into clinical trials is often seen as an ethical mandate because patients are recruited over a certain period of time and there is the need to access outcome during a follow up. Now you can increase overall sample size and modify/change many other aspects of trial design. While increased flexibility fits the needs of early drug development, application of these methods must be carefully validated against the confirmatory aims of studies in later drug development.
Conference highlights include: * Hear Case Studies Featuring Unpublished Data from Eli Lilly and Company and Millennium Pharmaceuticals, Inc. * Gain Insight into What to Consider for Dose Selection of Seamless Phase II/III Trials * Learn How to Use Biomarker-Based Adaptive Designs in Decision-Making Processes * Discover How to Use Bayesian Response Adaptive Designs in Early Proof of Concept Studies * Learn How to Choose a Flexible Sample Size Strategy and Carry it through Trial To register and view the complete agenda: http://www.ibclifesciences.com/3136 Phone: +1 (508) 616-5550
A number of Industry professionals from leading pharmaceutical and biotech companies will be attending:
Allergan Inc. Amgen, Baxter AG Berlex Inc. Cytel Software Corp. Daiichi Medical Research Family Health International Forest Laboratories Inc. GlaxoSmithKline ICTI Medicines Company Merck & Co. Merck Capital Ventures Millennium Pharmaceuticals Netherland Cancer Institute Novartis Pharmaceuticals Novo Nordisk A/S Orion Pharma Quintiles Inc. Rinat Neuroscience RJC Consulting Sanofi Aventis Serono Laboratories Titan Pharmaceuticals Inc. Transtech Pharma Inc. University of Washington Wyeth Research and more Contact: Heather Teepe Marketing Manager IBC Life Sciences +1 (508) 614-1494
IBC Life Sciences
CONTACT: Heather Teepe, Marketing Manager of IBC Life Sciences, +1-508-614-1494
Web site: http://www.lifesciencesinfo.com/
Source: PRNewswire
Related Articles
- The Cost Of Running Trials Approaches 30% Of Pharmaceutical Companies' Entire Drug Development Budgets, However 75% Of Patient Studies Fail To Make Their Timelines
- Pharsight Invited to Present on Model-Based Drug Development at Amsterdam Pharmaceutical Sciences World Congress on April 24, 2007
- European Union Meeting Performance Goals for New Drug Review, but Lags Behind U.S. In New Drug Availability, According to Tufts Center for the Study of Drug Development
- Big Pharma May Be Emerging From R&Amp;D Productivity Doldrums, According to the Tufts Center for the Study of Drug Development
- New Approaches to Assessing Drug Safety Will Help Reduce Development Time and Costs, According to Industry Panel Convened By the Tufts Center for the Study of Drug Development
- After Years of Declining R&D Productivity, Drug Development Is Poised to Take Off, According to Tufts Center for the Study of Drug Development
- Bioxel Pharma Secures Financing for Anticancer Drug Development From the Natural Sciences and Engineering Research Council of Canada
- New Drugs Are Taking Longer to Bring to Market in the U.S., According to Tufts Center for the Study of Drug Development
- No Link Between Drug Safety in U.S. And Approval Speed, According to Tufts Center for the Study of Drug Development
 |
 |
User Comments (0)
RSS Feeds